Supplemental Table 9.Baseline characteristic between dose levels of steroid use per day in matched patients with steroid prior to cardiac arrest

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Non- steroid |  | 1st Quartile |  | 2nd Quartile |  | 3rd Quartile |  | 4th Quartile |
| **Baseline characterisitics** |  | n=2188 |  | n=464 |  | n=547 |  | n=569 |  | n=608 |
|  |  | n(%) |  | n(%) |  | n(%) |  | n(%) |  | n(%) |
| Age (years) |  | 70.24±14.86 |  | 70.10±14.13 |  | 70.79±14.72 |  | 70.79±14.81 |  | 69.35±15.00 |
| Gender (Male) |  | 1307 (59.73%) |  | 249 (53.66%) |  | 335 (61.24%) |  | 337 (59.23%) |  | 363 (59.7%) |
| Presenting complaint | |  |  |  |  |  |  |  |  |  |
|  | Cardiac event | 417 (19.06%) |  | 91 (19.61%) |  | 90 (16.45%) |  | 113 (19.86%) |  | 118 (19.41%) |
|  | Respiratory event | 312 (14.26%) |  | 78 (16.81%) |  | 81 (14.81%) |  | 79 (13.88%) |  | 87 (14.31%) |
|  | Other event | 474 (21.66%) |  | 123 (26.51%) |  | 129 (23.58%) |  | 114 (20.04%) |  | 109 (17.93%) |
|  | Unknown | 985 (45.02%) |  | 172 (37.07%) |  | 247 (45.16%) |  | 263 (46.22%) |  | 294 (48.36%) |
| Diabetes mellitus |  | 801 (36.61%) |  | 208 (44.83%) |  | 192 (35.1%) |  | 194 (34.09%) |  | 193 (31.74%) |
| Hypertension |  | 1248 (57.04%) |  | 302 (65.09%) |  | 309 (56.49%) |  | 312 (54.83%) |  | 303 (49.84%) |
| Coronary artery disease | | 509 (23.26%) |  | 153 (32.97%) |  | 137 (25.05%) |  | 113 (19.86%) |  | 121 (19.9%) |
| Heart failure |  | 424 (19.38%) |  | 128 (27.59%) |  | 111 (20.29%) |  | 94 (16.52%) |  | 108 (17.76%) |
| Atrial fibrillation |  | 177 (8.09%) |  | 35 (7.54%) |  | 51 (9.32%) |  | 41 (7.21%) |  | 47 (7.73%) |
| Chronic kidney disease | | 288 (13.16%) |  | 92 (19.83%) |  | 79 (14.44%) |  | 61 (10.72%) |  | 54 (8.88%) |
| Malignancy |  | 366 (16.73%) |  | 71 (15.3%) |  | 97 (17.73%) |  | 115 (20.21%) |  | 88 (14.47%) |
| Chronic obstructive lung disease | | 703 (32.13%) |  | 123 (26.51%) |  | 169 (30.9%) |  | 177 (31.11%) |  | 230 (37.83%) |
| Asthma |  | 301 (13.76%) |  | 41 (8.84%) |  | 46 (8.41%) |  | 71 (12.48%) |  | 162 (26.64%) |
| Adrenal insufficiency | | 27 (1.23%) |  | 2 (0.43%) |  | 7 (1.28%) |  | 15 (2.64%) |  | 9 (1.48%) |
| Autoimmune disease | | 69 (3.15%) |  | 12 (2.59%) |  | 16 (2.93%) |  | 21 (3.69%) |  | 23 (3.78%) |
| Shockable rhythm |  | 519 (23.72%) |  | 110 (23.71%) |  | 134 (24.5%) |  | 115 (20.21%) |  | 145 (23.85%) |
| Epinephrine dosage (mg) | | 5.56±4.65 |  | 4.27±3.80 |  | 5.73±5.70 |  | 5.88±4.71 |  | 6.24±4.83 |
| Vasopressin |  | 4 (0.18%) |  | 0 (0%) |  | 2 (0.37%) |  | 1 (0.18%) |  | 3 (0.49%) |
| Medical center |  | 654 (29.89%) |  | 141 (30.39%) |  | 174 (31.81%) |  | 160 (28.12%) |  | 177 (29.11%) |
| Urbanization level of residence | | |  |  |  |  |  |  |  |  |
|  | 1 (high) | 523 (23.9%) |  | 111 (23.92%) |  | 131 (23.95%) |  | 135 (23.73%) |  | 153 (25.16%) |
|  | 2 | 925 (42.28%) |  | 206 (44.4%) |  | 235 (42.96%) |  | 231 (40.6%) |  | 269 (44.24%) |
|  | 3 | 191 (8.73%) |  | 42 (9.05%) |  | 53 (9.69%) |  | 53 (9.31%) |  | 45 (7.4%) |
|  | ≥ 4 (low) | 549 (25.09%) |  | 105 (22.63%) |  | 128 (23.4%) |  | 150 (26.36%) |  | 141 (23.19%) |
| Geographic distribution | |  |  |  |  |  |  |  |  |  |
|  | Taipei | 780 (35.65%) |  | 155 (33.41%) |  | 190 (34.73%) |  | 196 (34.45%) |  | 225 (37.01%) |
|  | Northern | 244 (11.15%) |  | 57 (12.28%) |  | 61 (11.15%) |  | 60 (10.54%) |  | 79 (12.99%) |
|  | Central | 659 (30.12%) |  | 139 (29.96%) |  | 181 (33.09%) |  | 173 (30.4%) |  | 153 (25.16%) |
|  | Southern | 240 (10.97%) |  | 53 (11.42%) |  | 57 (10.42%) |  | 69 (12.13%) |  | 66 (10.86%) |
|  | Kaopin | 169 (7.72%) |  | 46 (9.91%) |  | 36 (6.58%) |  | 54 (9.49%) |  | 48 (7.89%) |
|  | Eastern | 96 (4.39%) |  | 14 (3.02%) |  | 22 (4.02%) |  | 17 (2.99%) |  | 37 (6.09%) |